Drugs / Semaglutide
Semaglutide
Regulatory milestones approvals, filings & regulatory actions · 14 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (7) | US (FDA) | WEGOVY | — | 2022-12-23 – 2026-03-19 | fda.gov ↗ |
| Label expansions (5) | US (FDA) | OZEMPIC | — | 2020-01-16 – 2025-10-17 | fda.gov ↗ |
| Approved | EU (EMA) | Ozempic | — | 2018-02-08 | europa.eu ↗ |
| Approved | US (FDA) | OZEMPIC | — | 2017-12-05 | fda.gov ↗ |
Trials 381 · started per year
today
US approved 2017
EU approved 2018
1
1
4
1
2
7
19
3
12
11
16
28
10
33
38
47
47
47
50
3
1
200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT07627191 | Jul 2026 → Jun 2028 expected | colorectal cancer, hepatocellular carcinoma, malignant pancreatic neoplasm | University of Arizona | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06807970 | Sep 2025 → Jul 2027 expected | osteoarthritis, knee | The University of Hong Kong | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06338553 | Jun 2024 → Mar 2027 expected | type 1 diabetes mellitus | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 0 | NCT05249881 | Mar → Dec 2022 | type 2 diabetes mellitus | Aga Khan University | Unknown | No outcome recorded |
| Phase 190 trials | ||||||
| Phase 1 | NCT07527195 | Apr 2026 → Apr 2028 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT07223983 | Mar → Oct 2026 expected | alcohol-related disorders | Yale University | Recruiting | No outcome recorded |
| Phase 1 | NCT06222437 | Feb 2026 | polycystic ovary syndrome | Methodist Health System | Withdrawn | No outcome recorded |
| Phase 1 | NCT07225816 | Nov 2025 → Jun 2026 overdue | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT07010432 | Jun 2025 → May 2028 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT06648031 | Dec 2024 → Jul 2025 | type 2 diabetes mellitus | Lexaria Bioscience Corp. | Completed | No outcome recorded |
| Phase 1 | NCT06716307 | Dec 2024 → Mar 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06642584 | Oct 2024 → Jul 2025 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06575738 | Oct 2024 → Sep 2027 expected | obesity disorder | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 1 | NCT05202353 | Oct 2024 → Dec 2026 expected | obesity disorder | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 1 | NCT06446531 | Sep 2024 → Jul 2027 expected | cardiovascular disorder, prediabetes syndrome | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 1 | NCT06422624 | Aug → Nov 2024 | type 2 diabetes mellitus | Bostal Drug Delivery Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT06403761 | May 2024 → Dec 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06149260 | Feb → Aug 2024 | systemic sclerosis | Second Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 1 | NCT06289504 | Feb → Oct 2024 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06207877 | Feb → Oct 2024 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06267092 | Feb 2024 → Apr 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06699329 | Jan → May 2024 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06097390 | Sep 2023 → Feb 2024 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05996874 | Aug 2023 → Apr 2024 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05751226 | Apr 2023 → Aug 2024 | obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05784402 | Mar 2023 → Feb 2024 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05766709 | Mar 2023 → Jan 2024 | metabolic dysfunction-associated steatohepatitis | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05671653 | Jan → Nov 2023 | obesity disorder | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT05689099 | Jan → May 2023 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05498610 | Aug → Oct 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05429593 | Jun 2022 → Mar 2023 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05435677 | Jun 2022 → Apr 2023 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05071898 | Apr 2022 → Nov 2026 expected | obesity disorder, type 2 diabetes mellitus | University of Maryland, Baltimore | Recruiting | No outcome recorded |
| Phase 1 | NCT05236517 | Feb → Sep 2022 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05227196 | Feb 2022 → Jun 2023 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05232708 | Jan → Aug 2022 | diabetes mellitus, noninsulin-dependent, 2 | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05153564 | Dec 2021 → Aug 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05129891 | Nov 2021 → Feb 2023 | low density lipoprotein cholesterol, mild elevation of, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04817644 | Sep 2021 → May 2023 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04940078 | Jul 2021 → Jan 2022 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04878406 | May → Jul 2021 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04779697 | Feb 2021 → Nov 2024 | obesity disorder | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT04524832 | Sep 2020 → Feb 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04513704 | Aug 2020 → Apr 2021 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04259801 | Feb 2020 → Mar 2022 | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04238962 | Feb → Oct 2020 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04152915 | Nov 2019 → May 2020 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04016974 | Oct 2019 → Jan 2021 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04109508 | Oct 2019 → Dec 2020 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04097600 | Sep 2019 → Dec 2020 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04032197 | Aug 2019 → Dec 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04012255 | Jul → Aug 2019 | obesity disorder | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 1 | NCT03842202 | Feb → Nov 2019 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03789578 | Jan → Oct 2019 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03707990 | Oct 2018 → Aug 2019 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03611322 | Aug 2018 → Jan 2019 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03600480 | Jul 2018 → Jun 2020 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03598621 | Jul 2018 → Jan 2019 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03574584 | Jun 2018 → Jul 2019 | metabolic disease, obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03466567 | Mar → Jul 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03357380 | Nov 2017 → Mar 2020 | NAFLD1 | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03288740 | Sep 2017 → Jul 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03010475 | Jan → Jun 2017 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02920385 | Oct 2016 → Apr 2017 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02877355 | Aug 2016 → Nov 2017 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02845219 | Jul → Dec 2016 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02773381 | Jun 2016 → Oct 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02557620 | Sep 2015 → Apr 2016 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02249871 | Sep 2014 → Apr 2015 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02249910 | Sep 2014 → Mar 2015 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02243098 | Sep 2014 → Apr 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02231684 | Sep 2014 → Jan 2015 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02212067 | Aug 2014 → May 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02210871 | Aug 2014 → Jun 2015 | liver disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02161588 | Jun → Nov 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02172313 | Jun → Oct 2014 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02146079 | May → Oct 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02147431 | May 2014 → May 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02079870 | Mar 2014 → Jan 2015 | diabetes mellitus, obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02070510 | Feb → Aug 2014 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02064348 | Feb 2014 → Apr 2015 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02060266 | Feb → Apr 2014 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02022254 | Dec 2013 → Aug 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02016911 | Dec 2013 → Jan 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02014259 | Dec 2013 → Oct 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01866748 | May 2013 → Apr 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01686945 | Sep 2012 → Apr 2013 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01572753 | Apr → Sep 2012 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01324505 | Mar 2011 → Jan 2012 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01037582 | Dec 2009 → May 2010 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00833716 | Feb 2009 → Jul 2010 | impaired renal function disease, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00851773 | Feb → Oct 2009 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00813020 | Jan → Apr 2009 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03144271 | Jun → Oct 2007 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT07642635 | Sep 2026 → Sep 2030 expected | Duchenne muscular dystrophy | Vanderbilt University Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07563699 | Jul 2026 → Apr 2028 expected | type 2 diabetes mellitus | Mapi Pharma Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07374328 | Jun 2025 → May 2026 overdue | type 2 diabetes mellitus | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06541509 | Jul 2024 → Jul 2025 overdue | heart failure, obesity disorder | University Medical Centre Ljubljana | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05746039 | Jan 2024 → Dec 2027 expected | chronic obstructive pulmonary disease, obesity disorder, pulmonary hypertension, pulmonary sarcoidosis | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07336862 | Jan 2024 → Dec 2027 expected | obesity disorder | China-Japan Friendship Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04702516 | Mar 2021 → Aug 2022 | — | Morten Frost | Unknown | No outcome recorded |
| Phase 268 trials | ||||||
| Phase 2 | NCT07430332 | Sep 2027 → Jun 2029 expected | type 1 diabetes mellitus | Children's Hospital Medical Center, Cincinnati | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07614412 | Jan 2027 → Jan 2028 expected | type 1 diabetes mellitus | Ministry of Health, Saudi Arabia | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07249554 | Sep 2026 → Jul 2028 expected | alcohol-related disorders | Johns Hopkins University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07509112 | Sep 2026 → Jan 2027 expected | methamphetamine dependence | Kirby Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07357740 | Aug 2026 → Aug 2027 | type 2 diabetes mellitus | Novo Nordisk A/S | Withdrawn | No outcome recorded |
| Phase 2 | NCT07511543 | Jun 2026 → Jun 2028 expected | ischemic stroke | Population Health Research Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07639021 | Jun 2026 → Jul 2027 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 2 | NCT07282769 | Jun 2026 → Feb 2027 expected | trichotillomania | University of Chicago | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07179120 | May → Aug 2026 overdue | male infertility | First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07523633 | Apr 2026 → Apr 2028 expected | cannabis dependence, substance abuse | Anders Fink-Jensen, MD, DMSci | Recruiting | No outcome recorded |
| Phase 2 | NCT07221214 | Apr 2026 → Oct 2029 expected | HIV infectious disease, alcohol-related disorders, cardiovascular disorder | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07107334 | Apr 2026 → Nov 2028 expected | endometrial endometrioid adenocarcinoma | University of Florida | Recruiting | No outcome recorded |
| Phase 2 | NCT07314528 | Apr 2026 → Sep 2028 expected | obesity disorder, rectal cancer | St. James's Hospital, Ireland | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07204249 | Feb 2026 → Feb 2030 expected | methamphetamine dependence | San Francisco Department of Public Health | Recruiting | No outcome recorded |
| Phase 2 | NCT07325500 | Feb 2026 → May 2028 expected | — | The University of Texas Health Science Center, Houston | Recruiting | No outcome recorded |
| Phase 2 | NCT07202247 | Jan 2026 → Apr 2028 expected | prostate carcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07040592 | Jan 2026 → Jun 2027 expected | HIV infectious disease, alcohol-related disorders | Yale University | Recruiting | No outcome recorded |
| Phase 2 | NCT07227948 | Jan 2026 → Jan 2029 expected | substance-related disorder | The University of Texas Health Science Center, Houston | Recruiting | No outcome recorded |
| Phase 2 | NCT07135245 | Jan 2026 → Sep 2030 expected | Alzheimer disease | Rune Skovgaard Rasmussen | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07200622 | Sep 2025 → Dec 2027 expected | Alzheimer disease | Imperial College London | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06691243 | Aug 2025 → Jul 2026 overdue | HIV infectious disease, substance-related disorder | University of Maryland, Baltimore | Recruiting | No outcome recorded |
| Phase 2 | NCT06639464 | Jun 2025 → Aug 2026 overdue | opiate dependence | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07610174 | Jun 2025 → Apr 2026 | cardiac valvular defect, heart failure | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 2 | NCT05829460 | Mar 2025 → Apr 2030 | endometrial disorder | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 2 | NCT06548490 | Jan 2025 → Nov 2026 expected | drug-induced mental disorder, opiate dependence | Milton S. Hershey Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06771115 | Jan → Sep 2025 | obesity disorder | Zomagen Biosciences Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06411210 | Jul 2024 → Apr 2028 expected | obesity disorder, type 1 diabetes mellitus | Yale University | Recruiting | No outcome recorded |
| Phase 2 | NCT06050577 | Jun 2024 → Jan 2026 overdue | type 2 diabetes mellitus | Odense University Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06409130 | May 2024 → Nov 2025 | alcoholic liver disease | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT06173778 | Apr 2024 → Jul 2026 overdue | obesity disorder | The University of Texas Health Science Center, Houston | Recruiting | No outcome recorded |
| Phase 2 | NCT05822609 | Apr 2024 → Jun 2027 expected | diabetic kidney disease, type 1 diabetes mellitus | University of Washington | Recruiting | No outcome recorded |
| Phase 2 | NCT06131372 | Apr 2024 → Sep 2025 | chronic kidney disease, obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT05424003 | Feb 2024 → Aug 2026 overdue | fatty liver disease | University of Virginia | Recruiting | No outcome recorded |
| Phase 2 | NCT06072963 | Jan 2024 → Dec 2027 expected | Alzheimer disease, cognitive impairment with or without cerebellar ataxia, metabolic syndrome X | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
| Phase 2 | NCT05938712 | Oct 2023 → Oct 2027 expected | disease related to solid organ transplantation | University Health Network, Toronto | Recruiting | No outcome recorded |
| Phase 2 | NCT06015893 | Oct 2023 → Dec 2030 expected | alcohol-related disorders, substance dependence | National Institute on Drug Abuse (NIDA) | Recruiting | No outcome recorded |
| Phase 2 | NCT06974825 | Aug 2023 → Aug 2024 | type 2 diabetes mellitus | BrightGene Bio-Medical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05897372 | Aug 2023 → Sep 2024 | diabetic kidney disease | Iain Bressendorff | Terminated | No outcome recorded |
| Phase 2 | NCT06005012 | Jul 2023 → Dec 2026 expected | NAFLD1, fibrotic liver disease, type 2 diabetes mellitus | University of California, San Diego | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05067621 | Jul 2023 → Dec 2026 expected | NAFLD1, glucose intolerance, obesity disorder, type 2 diabetes mellitus | Yale University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05891587 | Jul 2023 → Jul 2025 | alcohol-related disorders | Oklahoma State University Center for Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT05895643 | Jun 2023 → Jul 2025 | alcohol abuse, alcohol dependence | Psychiatric Centre Rigshospitalet | Completed | No outcome recorded |
| Phase 2 | NCT05537233 | Apr 2023 → Aug 2024 | obesity disorder, type 1 diabetes mellitus | Viral N. Shah | Completed | No outcome recorded |
| Phase 2 | NCT05616013 | Nov 2022 → May 2024 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT05254314 | Oct 2022 → Sep 2026 expected | asthma | Vanderbilt University Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05530577 | Oct 2022 → May 2024 | nicotine dependence | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT05520775 | Sep 2022 → Apr 2024 | alcohol-related disorders | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT05302596 | Sep 2022 → Oct 2023 | obesity disorder | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 2 | NCT05486065 | Aug 2022 → Oct 2023 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT05356104 | May 2022 → May 2027 expected | cerebrovascular disorder | Chinese University of Hong Kong | Recruiting | No outcome recorded |
| Phase 2 | NCT05173714 | Dec 2021 → Dec 2026 expected | chronic kidney disease, obesity disorder | Srinvasan Beddhu | Recruiting | No outcome recorded |
| Phase 2 | NCT05144984 | Nov 2021 → Feb 2023 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT04466345 | Oct 2021 → Dec 2024 | major depressive disorder | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT04615871 | Sep 2021 → Mar 2022 | COVID-19 | Vladimír Džavík | Unknown | No outcome recorded |
| Phase 2 | NCT05016882 | Aug 2021 → Dec 2024 | metabolic dysfunction-associated steatohepatitis | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT04971785 | Aug 2021 → Nov 2024 | metabolic dysfunction-associated steatohepatitis | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT04982575 | Aug 2021 → Jul 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT04216589 | Feb 2021 → Mar 2023 | HIV infectious disease, NAFLD1 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT04143945 | Oct 2019 → Jan 2020 | obesity and hypopigmentation, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT03987074 | Jul 2019 → Jul 2020 | metabolic dysfunction-associated steatohepatitis | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT03884075 | Jul 2019 → Aug 2026 overdue | NAFLD1, metabolic dysfunction-associated steatohepatitis | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Recruiting | No outcome recorded |
| Phase 2 | NCT04007107 | Jun → Jul 2019 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT03987451 | Jun 2019 → Apr 2021 | metabolic dysfunction-associated steatohepatitis | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT04019197 | May 2019 → Apr 2024 overdue | HIV infectious disease, localized lipodystrophy, obesity disorder | Case Western Reserve University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02970942 | Nov 2016 → Feb 2020 | metabolic dysfunction-associated steatohepatitis | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT02453711 | Oct 2015 → Mar 2017 | metabolic disease, obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT02461589 | Sep 2015 → Oct 2016 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT00696657 | Jun 2008 → Feb 2009 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2/39 trials | ||||||
| Phase 2/3 | NCT06913023 | Jan 2026 → Nov 2027 expected | — | University Health Network, Toronto | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07223242 | Feb 2025 → Dec 2026 expected | cardiomyopathy, heart failure | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06896981 | Feb → Oct 2025 overdue | obesity disorder, polycystic ovary syndrome | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06387199 | Dec 2024 → Jan 2027 expected | type 1 diabetes mellitus | McGill University Health Centre/Research Institute of the McGill University Health Centre | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06423599 | Apr 2024 → Dec 2027 expected | heart failure, obesity disorder | Jens D Hove, MD,PHD | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05788965 | Oct 2023 → Dec 2024 | cystic fibrosis, cystic fibrosis-related diabetes | University of Minnesota | Completed | No outcome recorded |
| Phase 2/3 | NCT05205928 | Oct 2022 → Apr 2024 | type 1 diabetes mellitus | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| Phase 2/3 | NCT03919929 | May 2019 → Oct 2023 | NAFLD1, polycystic ovary syndrome | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 2/3 | NCT03899402 | May 2019 → Jan 2026 overdue | type 1 diabetes mellitus | State University of New York at Buffalo | Active not recruiting | No outcome recorded |
| Phase 3108 trials | ||||||
| Phase 3 | NCT07218354 | Jul 2026 → Apr 2028 expected | alcohol-related disorders | VA Office of Research and Development | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07357766 | Jun 2026 → Nov 2027 | obesity disorder | Novo Nordisk A/S | Withdrawn | No outcome recorded |
| Phase 3 | NCT07021937 | Jun 2026 → Apr 2031 expected | obesity and hypopigmentation | University of Colorado, Denver | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06934655 | Jun 2026 → Nov 2030 expected | — | Children's Hospital Los Angeles | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07581145 | Apr 2026 → Dec 2028 expected | ulcer of lower limbs | Bispebjerg Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07428746 | Apr 2026 → Nov 2028 expected | type 2 diabetes mellitus | Emory University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07059377 | Feb → Jul 2026 overdue | nicotine dependence, type 2 diabetes mellitus | Ottawa Heart Institute Research Corporation | Recruiting | No outcome recorded |
| Phase 3 | NCT07294950 | Feb 2026 → Sep 2028 expected | obesity disorder | Mount Sinai Hospital, Canada | Recruiting | No outcome recorded |
| Phase 3 | NCT07392151 | Feb 2026 → Oct 2029 expected | coronary atherosclerosis, prediabetes syndrome | Michael Mæng | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07253285 | Jan 2026 → Mar 2030 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT07271251 | Dec 2025 → Jun 2026 overdue | type 2 diabetes mellitus | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07030621 | Jul 2025 → Jul 2027 expected | ischemic stroke | RenJi Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06946628 | Jun 2025 → Dec 2028 expected | diabetes mellitus | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06894784 | Apr 2025 → Jan 2027 expected | type 1 diabetes mellitus | McGill University Health Centre/Research Institute of the McGill University Health Centre | Recruiting | No outcome recorded |
| Phase 3 | NCT06937060 | Mar 2025 → Jul 2026 overdue | obesity disorder, psoriasis | The University of Hong Kong | Recruiting | No outcome recorded |
| Phase 3 | NCT06780449 | Feb 2025 → Aug 2028 expected | obesity disorder | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06788626 | Feb 2025 → Feb 2028 expected | ischemic stroke, large artery stroke | Wei Hu | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06534411 | Nov 2024 → Jun 2026 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT06616961 | Nov 2024 → Feb 2025 overdue | obesity disorder, type 2 diabetes mellitus | Popular Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06388187 | Jun 2024 → Apr 2026 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT06361823 | May → Dec 2024 | pseudotumor cerebri | Capital Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT06339086 | Apr 2024 → Aug 2025 | type 2 diabetes mellitus | Chengdu Brilliant Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT06083675 | Jan 2024 → Jan 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Withdrawn | No outcome recorded |
| Phase 3 | NCT06221969 | Jan 2024 → Mar 2026 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT06131437 | Nov 2023 → Dec 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT05819853 | Nov 2023 → Feb 2028 expected | obesity disorder, polycystic ovary syndrome | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 3 | NCT06065540 | Sep 2023 → Nov 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT05813912 | Sep 2023 → Apr 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT06041217 | Sep 2023 → Apr 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT05996848 | Aug 2023 → Jan 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT05726227 | Jul 2023 → Oct 2025 overdue | obesity disorder | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05819138 | Jun 2023 → Oct 2027 expected | type 1 diabetes mellitus | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 3 | NCT05891496 | Jun 2023 → Aug 2024 | Alzheimer disease | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT05890976 | May 2023 → Jan 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT05813925 | Apr 2023 → Jan 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT05586802 | Mar 2023 → Apr 2027 expected | Klinefelter syndrome | Georgios Papadakis | Recruiting | No outcome recorded |
| Phase 3 | NCT05669755 | Mar 2023 → Sep 2027 expected | cardiovascular disorder | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05394519 | Feb 2023 → Jan 2025 | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT05649137 | Jan 2023 → Oct 2024 | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT05646706 | Jan 2023 → Oct 2024 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT05073835 | Nov 2022 → Mar 2025 overdue | diabetes mellitus, metabolic syndrome X, obesity disorder | University College, London | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05567796 | Nov 2022 → Oct 2024 overdue | obesity disorder | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05564117 | Oct 2022 → Apr 2024 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT05444153 | Oct 2022 → Oct 2024 | type 2 diabetes mellitus | Novo Nordisk A/S | Withdrawn | No outcome recorded |
| Phase 3 | NCT05514535 | Aug 2022 → Mar 2025 | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT04998136 | Aug 2022 → Oct 2023 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT05816057 | Jul 2022 → Jul 2023 | type 2 diabetes mellitus | Hangzhou Jiuyuan Gene Engineering Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05305794 | Jul 2022 → Aug 2028 expected | diabetes mellitus | Centre Hospitalier Universitaire Dijon | Recruiting | No outcome recorded |
| Phase 3 | NCT05259033 | Apr 2022 → Dec 2023 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT04889183 | Mar 2022 → May 2024 | obesity disorder, proteinuria | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 3 | NCT05013229 | Nov 2021 → Nov 2023 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT05132088 | Nov 2021 → Jul 2023 | morbid obesity | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT05071417 | Nov 2021 → Dec 2024 | coronary atherosclerosis | Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León | Unknown | No outcome recorded |
| Phase 3 | NCT05064735 | Oct 2021 → Jul 2023 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT05035095 | Sep 2021 → Mar 2023 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT05040971 | Sep 2021 → Jan 2023 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT04916470 | Jun 2021 → Oct 2023 | diabetes mellitus, noninsulin-dependent, 2 | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT04777409 | May 2021 → Sep 2025 | Alzheimer disease | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT04777396 | May 2021 → Sep 2025 | Alzheimer disease | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT04865770 | Apr 2021 → Nov 2024 | chronic kidney disease, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT04822181 | Apr 2021 → Apr 2029 expected | metabolic dysfunction-associated steatohepatitis | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04788511 | Mar 2021 → Apr 2023 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT04707469 | Jan 2021 → Mar 2023 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT04251156 | Dec 2020 → Aug 2022 | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT04596631 | Nov 2020 → Apr 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT04560998 | Oct 2020 → Jun 2024 | peripheral arterial disease, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT06489457 | Sep 2020 → May 2023 | hypogonadism, obesity disorder, type 2 diabetes mellitus | University Medical Centre Ljubljana | Completed | No outcome recorded |
| Phase 3 | NCT04287179 | Mar → Nov 2020 | type 2 diabetes mellitus | Novo Nordisk A/S | Withdrawn | No outcome recorded |
| Phase 3 | NCT04447859 | Feb 2020 → May 2022 | type 2 diabetes mellitus | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT04102189 | Oct 2019 → Mar 2022 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT04109547 | Oct 2019 → Sep 2021 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT04074161 | Sep 2019 → Mar 2021 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT04017832 | Jul 2019 → Oct 2021 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03989232 | Jun 2019 → Sep 2020 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03819153 | Jun 2019 → Jan 2024 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03914326 | Jun 2019 → Aug 2024 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03811561 | May 2019 → Nov 2027 expected | type 2 diabetes mellitus | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03811574 | Jan 2019 → Nov 2020 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03574597 | Oct 2018 → Jun 2023 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03693430 | Oct 2018 → Jan 2021 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03689374 | Oct 2018 → Feb 2021 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03611582 | Aug 2018 → Mar 2020 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03552757 | Jun 2018 → Mar 2020 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03548987 | Jun 2018 → Feb 2020 | metabolic disease, obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03548935 | Jun 2018 → Mar 2020 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03061214 | Aug 2017 → Mar 2019 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03191396 | Jun 2017 → Jul 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03086330 | Mar 2017 → Jul 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03136484 | Mar 2017 → Oct 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03021187 | Feb 2017 → Jan 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02692716 | Jan 2017 → Sep 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03018028 | Jan 2017 → Jan 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT03015220 | Jan 2017 → Jul 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02906930 | Sep 2016 → Oct 2017 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02849080 | Sep 2016 → Feb 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02827708 | Sep 2016 → Apr 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02863419 | Aug 2016 → Aug 2017 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02863328 | Aug 2016 → Aug 2017 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02607865 | Feb 2016 → Feb 2017 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02648204 | Jan 2016 → Apr 2017 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02305381 | Dec 2014 → Nov 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02254291 | Oct 2014 → Nov 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02128932 | Aug 2014 → Sep 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02207374 | Aug 2014 → Feb 2016 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02054897 | Feb 2014 → May 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01885208 | Dec 2013 → Jul 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01930188 | Dec 2013 → Oct 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01720446 | Feb 2013 → Mar 2016 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 464 trials | ||||||
| Phase 4 | NCT07462663 | Jan 2027 → Apr 2031 expected | atypical endometrial hyperplasia, endometrial cancer, intraepithelial neoplasia, morbid obesity | Hospital Universitari de Bellvitge | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07027969 | Nov 2026 → Dec 2029 expected | atrial fibrillation, obesity disorder | Ali Aminian | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06977438 | Oct 2026 → Jan 2031 expected | obesity disorder | University of Minnesota | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07389941 | Oct 2026 → Apr 2029 expected | atrial fibrillation | University of Luebeck | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07617155 | Sep 2026 → Sep 2028 expected | acute pancreatitis, hypertriglyceridemia, recurrent acute pancreatitis | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07592546 | Aug 2026 → Dec 2028 expected | morbid obesity | Alain Dagher | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07485062 | May 2026 → May 2029 expected | subjective cognitive decline, type 2 diabetes mellitus | Western University, Canada | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07558863 | Apr 2026 → Mar 2028 expected | diabetic autonomic neuropathy, type 2 diabetes mellitus | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT07483801 | Mar 2026 → Apr 2027 expected | cardiovascular disorder | Cambridge University Hospitals NHS Foundation Trust | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07242534 | Jan 2026 → Feb 2027 expected | infertility disorder, obesity disorder | Fundacion Dexeus | Recruiting | No outcome recorded |
| Phase 4 | NCT07213466 | Jan 2026 → Feb 2028 expected | bipolar I disorder, bipolar II disorder, obesity disorder, schizoaffective disorder | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT07275697 | Dec 2025 → Dec 2028 expected | atrial fibrillation, obesity disorder | Emma Svennberg | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07251556 | Dec 2025 → Jan 2027 expected | psoriatic arthritis | Chinese University of Hong Kong | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07017270 | Nov 2025 → Jul 2027 expected | end stage renal failure, type 2 diabetes mellitus | Unity Health Toronto | Recruiting | No outcome recorded |
| Phase 4 | NCT07178145 | Nov 2025 → Sep 2029 expected | symptomatic heart failure | University of Virginia | Recruiting | No outcome recorded |
| Phase 4 | NCT06801015 | Oct 2025 → Jan 2028 expected | obesity disorder | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 4 | NCT07073053 | Oct 2025 → Jul 2028 expected | coronary artery disorder, type 2 diabetes mellitus | Taipei Veterans General Hospital, Taiwan | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07165158 | Sep 2025 → Dec 2026 expected | osteoporosis, type 2 diabetes mellitus | The First Affiliated Hospital of Xiamen University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07136714 | Sep 2025 → Sep 2027 expected | major depressive disorder | Nordsjaellands Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07314684 | Sep 2025 → Mar 2027 expected | type 2 diabetes mellitus | Federico II University | Recruiting | No outcome recorded |
| Phase 4 | NCT07513168 | Aug 2025 → Aug 2026 overdue | obesity disorder | Asian Institute Of Medical Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT07254572 | Jul 2025 → Aug 2029 expected | coronary atherosclerosis, prediabetes syndrome | National Institute of Cardiology, Warsaw, Poland | Recruiting | No outcome recorded |
| Phase 4 | NCT06908694 | Jul 2025 → Jul 2026 overdue | prostate cancer | Hamilton Health Sciences Corporation | Recruiting | No outcome recorded |
| Phase 4 | NCT07239570 | Jun 2025 → Jun 2028 expected | chronic kidney disease | Peter Rossing | Recruiting | No outcome recorded |
| Phase 4 | NCT06852391 | Jun 2025 → Dec 2027 expected | obesity disorder | McMaster University | Recruiting | No outcome recorded |
| Phase 4 | NCT06851962 | May 2025 → Jun 2026 overdue | type 2 diabetes mellitus | Fundación para la Investigación del Hospital Clínico de Valencia | Active not recruiting | No outcome recorded |
| Phase 4 | NCT07057310 | May 2025 → Dec 2026 expected | obesity disorder | Mayo Clinic | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06706284 | Apr 2025 → Sep 2028 expected | spinal cord injury, type 2 diabetes mellitus | Marzieh Salehi | Recruiting | No outcome recorded |
| Phase 4 | NCT06814938 | Feb 2025 → Dec 2027 expected | obesity disorder | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06754163 | Jan 2025 → Jul 2027 expected | obesity disorder, psychiatric disorder | St Andrew's Healthcare | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06792422 | Jan 2025 → Aug 2028 expected | open-angle glaucoma | Glostrup University Hospital, Copenhagen | Recruiting | No outcome recorded |
| Phase 4 | NCT06396416 | Sep 2024 → Sep 2026 expected | chronic kidney disease, obesity disorder | Western University, Canada | Recruiting | No outcome recorded |
| Phase 4 | NCT06571383 | Sep 2024 → Nov 2028 expected | obesity disorder | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06557811 | Sep 2024 overdue | acute myocardial infarction | University of Sao Paulo General Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06468748 | Aug 2024 → Mar 2025 | obesity disorder | United States Army Research Institute of Environmental Medicine | Withdrawn | No outcome recorded |
| Phase 4 | NCT06461377 | Jun 2024 → Dec 2026 expected | diabetic autonomic neuropathy, type 2 diabetes mellitus | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT06003153 | Mar 2024 → May 2027 expected | type 2 diabetes mellitus | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06243536 | Feb → Dec 2024 | eating disorder, obesity disorder, type 2 diabetes mellitus | University Hospital Sestre Milosrdnice | Unknown | No outcome recorded |
| Phase 4 | NCT06959784 | Jan 2024 → Dec 2026 expected | cerebrovascular disorder, diabetes mellitus | China-Japan Friendship Hospital | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06042153 | Dec 2023 → Sep 2027 expected | end stage renal failure, type 2 diabetes mellitus | University of Texas Southwestern Medical Center | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05702905 | May 2023 → Dec 2024 | polycystic ovary syndrome | Peking University First Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT06475586 | May 2023 → Mar 2024 | psoriasis, type 2 diabetes mellitus | University of Banja Luka | Completed | No outcome recorded |
| Phase 4 | NCT05209165 | May 2023 → May 2027 | atrial fibrillation, obesity disorder | San Francisco Veterans Affairs Medical Center | Suspended | No outcome recorded |
| Phase 4 | NCT05870462 | Apr 2023 → Dec 2024 | atherosclerosis, diabetes mellitus, noninsulin-dependent, 2, obesity disorder | Canadian Medical and Surgical Knowledge Translation Research Group | Unknown | No outcome recorded |
| Phase 4 | NCT05786521 | Apr 2023 → May 2024 | prediabetes syndrome, type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 4 | NCT07272343 | Feb 2023 → Jun 2026 overdue | type 2 diabetes mellitus | Second Affiliated Hospital of Nanchang University | Recruiting | No outcome recorded |
| Phase 4 | NCT05579249 | Jan 2023 → Nov 2024 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT05597202 | Jan 2023 → Mar 2024 | type 2 diabetes mellitus | Academic Medical Center - University of Amsterdam | Unknown | No outcome recorded |
| Phase 4 | NCT05195944 | Oct 2022 → Dec 2026 expected | NAFLD1, diabetes mellitus, metabolic dysfunction-associated steatohepatitis | University Health Network, Toronto | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06027567 | Sep 2022 → Jan 2025 | obesity disorder, pseudotumor cerebri | Rigmor Højland Jensen | Completed | No outcome recorded |
| Phase 4 | NCT05442450 | Jul 2022 → Jun 2023 | obesity disorder | Asian Institute of Gastroenterology, India | Unknown | No outcome recorded |
| Phase 4 | NCT05533632 | Apr 2022 → Jan 2024 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT04854083 | Feb 2022 → Aug 2025 | type 2 diabetes mellitus | Kirsi Pietiläinen | Unknown | No outcome recorded |
| Phase 4 | NCT04873050 | Jan 2022 → Jan 2026 overdue | prediabetes syndrome, puerperal disorder | Woman's | Recruiting | No outcome recorded |
| Phase 4 | NCT04979130 | Jan 2022 → Oct 2024 | type 2 diabetes mellitus | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT05119179 | Nov 2021 → Oct 2026 expected | prediabetes syndrome | The University of Texas Health Science Center, Houston | Recruiting | No outcome recorded |
| Phase 4 | NCT05606471 | Sep 2021 → Jul 2023 | type 2 diabetes mellitus | University of Nottingham | Unknown | No outcome recorded |
| Phase 4 | NCT05035082 | Sep 2021 → Jun 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT04639414 | Mar 2021 → Jan 2025 | NAFLD1, metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus | German Diabetes Center | Completed | No outcome recorded |
| Phase 4 | NCT04538352 | Jan 2021 → Mar 2023 | type 2 diabetes mellitus | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 4 | NCT04189848 | Dec 2019 → Jan 2020 | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT04263415 | Nov 2019 → May 2020 | oral sensibility, disturbance of, polycystic ovary syndrome | University Medical Centre Ljubljana | Completed | No outcome recorded |
| Phase 4 | NCT03292315 | Oct 2018 → Mar 2020 | obesity disorder, prediabetes syndrome, spinal cord injury | James J. Peters Veterans Affairs Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03596450 | Jul 2018 → Jun 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase not applicable31 trials | ||||||
| — | NCT07586150 | Oct 2028 → Jul 2030 expected | bipolar disorder, major depressive disorder, schizophrenia | Ludwig-Maximilians - University of Munich | Not yet recruiting | No outcome recorded |
| — | NCT07677995 | Jul → Dec 2026 expected | cardiovascular disorder, type 2 diabetes mellitus | University of Ulster | Enrolling by invitation | No outcome recorded |
| — | NCT07621640 | Jun 2026 → Feb 2028 expected | abdominal obesity-metabolic syndrome, obesity disorder | Hallym University | Not yet recruiting | No outcome recorded |
| — | NCT06546384 | May → Dec 2026 expected | alcohol-related disorders, fatty liver disease, obesity disorder | Insel Gruppe AG, University Hospital Bern | Not yet recruiting | No outcome recorded |
| — | NCT07633639 | May 2026 → May 2028 expected | obesity disorder | China-Japan Friendship Hospital | Recruiting | No outcome recorded |
| — | NCT07599046 | Apr 2026 → Jan 2027 expected | type 2 diabetes mellitus | Eighth Affiliated Hospital, Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| — | NCT07391267 | Feb 2026 → Dec 2028 expected | chronic kidney disease, metabolic dysfunction-associated steatotic liver disease | Institute of Liver and Biliary Sciences, India | Not yet recruiting | No outcome recorded |
| — | NCT07319975 | Dec 2025 → Oct 2026 expected | obesity disorder | Istanbul Galata University | Not yet recruiting | No outcome recorded |
| — | NCT07091500 | Aug 2025 → Aug 2028 expected | obesity disorder, skeletal muscle disorder | Washington University School of Medicine | Recruiting | No outcome recorded |
| — | NCT06924697 | Jun 2025 → Jan 2026 overdue | nicotine dependence, type 2 diabetes mellitus | Shanghai East Hospital | Enrolling by invitation | No outcome recorded |
| — | NCT06989203 | Jun 2025 → Dec 2026 expected | obesity disorder | Chinese Academy of Sciences | Recruiting | No outcome recorded |
| — | NCT07293325 | Jun 2025 → Apr 2027 expected | obesity disorder | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| — | NCT06715514 | Feb 2025 → Dec 2026 expected | type 2 diabetes mellitus | Lia Bally | Recruiting | No outcome recorded |
| — | NCT06608433 | Jan → Oct 2025 | adrenocortical insufficiency | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| — | NCT06555146 | Aug 2024 → Mar 2025 overdue | chronic kidney disease, type 2 diabetes mellitus | Bispebjerg Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06363487 | Jun → Dec 2024 | — | University of Oxford | Completed | No outcome recorded |
| — | NCT06318442 | May 2024 → Jun 2027 expected | hyperglycemia | Imperial College London | Recruiting | No outcome recorded |
| — | NCT07368855 | May 2024 → Jul 2025 | depressive disorder, obesity disorder | University of California, San Diego | Completed | No outcome recorded |
| — | NCT06390501 | Apr 2024 → Aug 2025 | obesity disorder | Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences | Completed | No outcome recorded |
| — | NCT06629688 | Nov 2023 → Apr 2024 | iron metabolism disease, type 2 diabetes mellitus | University Hospital Dubrava | Completed | No outcome recorded |
| — | NCT06060392 | Oct 2023 → Sep 2025 overdue | diabetes mellitus | Medanta, The Medicity, India | Recruiting | No outcome recorded |
| — | NCT05390307 | Apr 2023 → Jan 2024 | type 1 diabetes mellitus | Dasman Diabetes Institute | Completed | No outcome recorded |
| — | NCT05779644 | Feb 2023 → Feb 2025 | abdominal obesity-metabolic syndrome, metabolic dysfunction-associated steatotic liver disease, type 2 diabetes mellitus | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT05501483 | Feb 2023 → Sep 2026 expected | type 2 diabetes mellitus | Karolinska Institutet | Recruiting | No outcome recorded |
| — | NCT05340868 | Sep 2022 → Dec 2025 overdue | obesity disorder, prediabetes syndrome | Medical University of Bialystok | Recruiting | No outcome recorded |
| — | NCT04174755 | Jun 2022 → Jan 2027 expected | HIV infectious disease, obesity disorder | University College Dublin | Recruiting | No outcome recorded |
| — | NCT05333003 | May 2022 → Aug 2026 overdue | schizophrenia | Centre for Addiction and Mental Health | Active not recruiting | No outcome recorded |
| — | NCT07539584 | Mar 2022 → Apr 2024 | metabolic dysfunction-associated steatotic liver disease, type 2 diabetes mellitus | Moscow Regional Research and Clinical Institute (MONIKI) | Completed | No outcome recorded |
| — | NCT05078255 | Jan 2022 → Jan 2025 | obesity disorder, type 2 diabetes mellitus | Asger Lund, MD | Completed | No outcome recorded |
| — | NCT04383197 | Dec 2019 → Aug 2021 | type 2 diabetes mellitus | University of Copenhagen | Unknown | No outcome recorded |
| — | NCT03498001 | Apr 2018 → Jun 2023 | type 2 diabetes mellitus | Centre Hospitalier Universitaire Dijon | Completed | No outcome recorded |
Also used as a comparator or background therapy in 151 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07092605 Comparator | Nov 2024 → Nov 2025 overdue | — | AgelessRx | Enrolling by invitation | No outcome recorded |
| Phase 117 trials | ||||||
| Phase 1 | NCT07430059 Comparator | Jul → Dec 2026 expected | obesity disorder | Vivani Medical, Inc | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07673900 Comparator | Jun 2026 → Feb 2027 expected | obesity disorder | Terrestrial Bio, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07539415 Comparator | May → Oct 2026 expected | obesity disorder, type 2 diabetes mellitus | Daewoong Pharmaceutical Co. LTD. | Recruiting | No outcome recorded |
| Phase 1 | NCT07465965 Comparator | Mar → Aug 2026 overdue | obesity disorder | Shanghai World Leader Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07087795 Background | Jul 2025 → Sep 2026 expected | type 1 diabetes mellitus | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06982859 Comparator | Jun 2025 → Dec 2026 expected | type 2 diabetes mellitus | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06972992 Background | Apr → Sep 2025 | — | Ascletis Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT06745284 Comparator | Mar 2025 → Jan 2027 expected | obesity disorder | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06830343 Comparator | Feb 2025 → Aug 2026 overdue | obesity disorder | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05670379 Comparator | Dec 2024 → Aug 2025 | morbid obesity, type 2 diabetes mellitus | Vivani Medical, Inc | Completed | No outcome recorded |
| Phase 1 | NCT06634927 Comparator | Sep → Nov 2024 | type 2 diabetes mellitus | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06497049 Comparator | Jun 2023 → May 2024 | — | Geropharm | Completed | No outcome recorded |
| Phase 1 | NCT05046873 Comparator | Sep 2021 → Jan 2022 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03951753 Comparator | Jun 2019 → Apr 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03638778 Comparator | Aug → Dec 2018 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01619345 Background | Jun → Aug 2012 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01272973 Comparator | Jan → Jul 2011 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07651319 Comparator | Jul 2026 → Jun 2029 expected | Alzheimer disease | The Methodist Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06057077 Comparator | Jan → Dec 2024 | type 1 diabetes mellitus | Ministry of Health, Saudi Arabia | Unknown | No outcome recorded |
| Phase 1/2 | NCT06827002 Comparator | Mar 2023 → Feb 2026 overdue | obesity disorder | University of Yaounde 1 | Active not recruiting | No outcome recorded |
| Phase 236 trials | ||||||
| Phase 2 | NCT07411378 Background | Jul 2026 → Jun 2027 expected | muscular atrophy, obesity disorder | Biophytis | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07668388 Comparator | Jun 2026 → Oct 2027 expected | type 2 diabetes mellitus | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 2 | NCT07613437 Comparator | Jun 2026 → Jun 2028 expected | intracerebral hemorrhage | Chinese University of Hong Kong | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07415954 Comparator | Apr 2026 → Sep 2027 expected | type 2 diabetes mellitus | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 2 | NCT07466017 Background | Apr 2026 → Apr 2027 expected | metabolic dysfunction-associated steatohepatitis, obesity disorder | Cascade Pharmaceuticals, Inc | Recruiting | No outcome recorded |
| Phase 2 | NCT07446998 Background | Mar 2026 → Oct 2027 expected | obesity disorder | Veru Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07505303 Background | Mar → Oct 2026 expected | obesity disorder | Eccogene | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07172867 Background | Jan 2026 | obesity disorder, type 2 diabetes mellitus | Halia Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT07187856 Comparator | Jan → Sep 2026 expected | type 2 diabetes mellitus | ProGen. Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07112872 Comparator | Aug 2025 → Nov 2026 expected | type 2 diabetes mellitus | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07073417 Comparator | Jul 2025 → Feb 2027 expected | obesity disorder | Hangzhou Sciwind Biosciences Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07101939 Comparator | Jun 2025 → Mar 2027 expected | muscular atrophy, obesity disorder | Actimed Therapeutics Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT07163624 Comparator | Mar → Nov 2025 | type 2 diabetes mellitus | The United Bio-Technology (Hengqin) Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06762314 Comparator | Jan 2025 → Sep 2027 expected | diabetes mellitus | Mostafa Bahaa | Recruiting | No outcome recorded |
| Phase 2 | NCT06717698 Comparator | Dec 2024 → Sep 2026 expected | chronic kidney disease | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 2 | NCT06579105 Comparator | Oct 2024 → Dec 2025 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT06577090 Background | Aug 2024 → Nov 2026 expected | obesity disorder | Skye Bioscience, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06449625 Comparator | Aug 2024 → Dec 2026 expected | chemotherapy-induced toxicity, gastrointestinal mucositis | Klaus Gottlob Müller | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06500429 Background | Jun → Sep 2024 | — | Neurogastrx, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT06282458 Background | Apr 2024 → Apr 2025 | muscular atrophy, obesity disorder | Veru Inc. | Completed | No outcome recorded |
| Phase 2 | NCT06299098 Background | Mar 2024 → May 2026 overdue | obesity disorder | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05892432 Comparator | Jan 2024 → Nov 2025 | alcohol-related disorders | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 2 | NCT06256549 Comparator | Aug 2023 → Jul 2024 | type 2 diabetes mellitus | Gan and Lee Pharmaceuticals, USA | Unknown | No outcome recorded |
| Phase 2 | NCT05920889 Comparator | Aug 2023 → Oct 2024 | ischemic stroke | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 2 | NCT05877547 Comparator | Jun 2023 → Dec 2025 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT05630586 Comparator | Apr 2023 → Sep 2025 overdue | ischemic stroke | Aarhus University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05579977 Comparator | Oct 2022 → Jul 2023 | obesity disorder, type 2 diabetes mellitus | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT04873245 Comparator | Mar 2022 → Jun 2026 | obesity disorder | University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT05193578 Comparator | Jan 2022 → Mar 2024 | prediabetes syndrome, schizophrenia | Jan Frystyk | Completed | No outcome recorded |
| Phase 2 | NCT04944992 Comparator | Aug 2021 → Oct 2022 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT04969939 Background | Jul 2021 → Dec 2022 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT04451837 Comparator | Sep 2020 → Dec 2021 overdue | type 2 diabetes mellitus | Region Skane | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04515849 Comparator | Aug 2020 → Mar 2022 | chronic kidney disease, type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT04153929 Comparator | Apr 2020 → Oct 2021 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT03659682 Comparator | Jan 2019 → Dec 2024 | Parkinson disease | Oslo University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01923181 Comparator | Dec 2013 → Dec 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT06975111 Comparator | Mar 2026 → Oct 2029 expected | cardiovascular disorder | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06619015 Background | Apr 2025 | obesity disorder, prediabetes syndrome | Esbjerg Hospital - University Hospital of Southern Denmark | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT05646199 Comparator | Mar → Sep 2025 | polycystic ovary syndrome | University of Hull | Unknown | No outcome recorded |
| Phase 342 trials | ||||||
| Phase 3 | NCT07668414 Comparator | Sep 2026 → Oct 2028 expected | obesity disorder | Novo Nordisk A/S | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07622810 Comparator | Sep 2026 → Dec 2027 expected | obesity disorder | Carnot Laboratories | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07628985 Comparator | Sep 2026 → Oct 2027 expected | type 2 diabetes mellitus | Carnot Laboratories | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07653477 Comparator | Jul 2026 → Feb 2028 expected | type 2 diabetes mellitus | The United Bio-Technology (Hengqin) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07662213 Comparator | Jul 2026 → May 2028 expected | type 2 diabetes mellitus | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT07564414 Comparator | May 2026 → Feb 2028 expected | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT07400107 Comparator | May 2026 → Dec 2028 expected | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07487103 Comparator | May → Dec 2026 expected | type 2 diabetes mellitus | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07090343 Comparator | Apr 2026 → Sep 2030 expected | aortic valve stenosis, heart failure | Leiden University Medical Center | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07284979 Comparator | Dec 2025 → Mar 2028 expected | obesity disorder | Kailera | Recruiting | No outcome recorded |
| Phase 3 | NCT07295223 Comparator | Dec 2025 → Aug 2026 overdue | ST-elevation myocardial infarction | Mexican Social Security Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT07297589 Comparator | Dec 2025 → Jan 2027 expected | ST-elevation myocardial infarction | Mexican Social Security Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT07285902 Comparator | Dec 2025 → Mar 2027 expected | obesity disorder | Fujian Shengdi Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06909006 Comparator | Oct 2025 → Jun 2028 expected | obesity disorder, type 1 diabetes mellitus | Nordsjaellands Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07150975 Comparator | Sep 2025 → Jun 2027 expected | — | Gan & Lee Pharmaceuticals. | Recruiting | No outcome recorded |
| Phase 3 | NCT07139548 Comparator | Aug 2025 → Dec 2026 expected | type 2 diabetes mellitus | Guangdong Raynovent Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07046273 Comparator | Aug 2025 → Aug 2028 expected | type 2 diabetes mellitus | Shandong New Time Pharmaceutical Co., LTD | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07064486 Comparator | Jul 2025 → Jul 2026 overdue | type 2 diabetes mellitus | BrightGene Bio-Medical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06884293 Comparator | May 2025 → Dec 2026 expected | metabolic dysfunction-associated steatotic liver disease, obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06499857 Comparator | Apr 2025 → Dec 2027 expected | atrial fibrillation, obesity disorder | University of Chicago | Recruiting | No outcome recorded |
| Phase 3 | NCT06738979 Comparator | Mar 2025 → Jul 2026 overdue | obesity disorder | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06778967 Comparator | Feb 2025 → Dec 2026 expected | type 2 diabetes mellitus | Gan & Lee Pharmaceuticals. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07036172 Comparator | Jan 2025 → Apr 2026 overdue | obesity disorder | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06716216 Comparator | Nov 2024 → Mar 2026 overdue | type 2 diabetes mellitus | BrightGene Bio-Medical Technology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06649344 Comparator | Oct 2024 → Sep 2026 expected | type 2 diabetes mellitus | Fujian Shengdi Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06633783 Comparator | Oct 2024 → May 2026 overdue | obesity disorder | Hangzhou Jiuyuan Gene Engineering Co. Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06604624 Comparator | Sep 2024 → Aug 2025 | — | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT06082063 Comparator | Jul 2024 → Jul 2029 expected | heart failure, kidney failure, type 1 diabetes mellitus | Steno Diabetes Center Copenhagen | Recruiting | No outcome recorded |
| Phase 3 | NCT06323161 Comparator | Mar 2024 → Sep 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT06323174 Comparator | Mar 2024 → Oct 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT06184568 Comparator | Feb 2024 → Sep 2025 | obesity disorder, type 2 diabetes mellitus | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT06161844 Comparator | Feb 2024 → May 2025 | type 2 diabetes mellitus | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT06260722 Comparator | Feb 2024 → Aug 2026 overdue | type 2 diabetes mellitus | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06045221 Comparator | Sep 2023 → Aug 2025 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT06739044 Comparator | Sep 2023 → Oct 2024 | type 2 diabetes mellitus | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05569772 Comparator | Sep 2023 → Jun 2029 expected | glucose intolerance | Universitaire Ziekenhuizen KU Leuven | Recruiting | No outcome recorded |
| Phase 3 | NCT05950516 Comparator | Jul 2023 → Nov 2024 | type 2 diabetes mellitus | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05822830 Comparator | Apr 2023 → Nov 2024 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT05087342 Comparator | Dec 2022 → May 2024 | obesity disorder | Loma Linda University | Completed | No outcome recorded |
| Phase 3 | NCT04885634 Comparator | Oct 2022 → Jan 2024 | atrial fibrillation | Axel Brandes | Withdrawn | No outcome recorded |
| Phase 3 | NCT04741074 Comparator | Jul 2021 → Jan 2023 | diabetic kidney disease, morbid obesity, type 2 diabetes mellitus | Geisinger Clinic | Terminated | No outcome recorded |
| Phase 3 | NCT03987919 Comparator | Jul 2019 → Jan 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 436 trials | ||||||
| Phase 4 | NCT07547878 Comparator | Apr 2026 → Mar 2029 expected | chronic kidney disease, type 2 diabetes mellitus | Baylor Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07554417 Comparator | Apr → Jun 2026 overdue | muscular atrophy, obesity disorder | William Marsh Rice University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07401992 Comparator | Jan 2026 → Feb 2027 expected | obesity disorder, psoriasis, type 2 diabetes mellitus | Hospital Universitario Dr. Jose E. Gonzalez | Recruiting | No outcome recorded |
| Phase 4 | NCT07058155 Comparator | Dec 2025 → Feb 2029 expected | cirrhosis of liver, morbid obesity, portal hypertension | The Cleveland Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT06954090 Comparator | Nov 2025 → Nov 2026 expected | diabetic kidney disease, proteinuria, type 2 diabetes mellitus | Steno Diabetes Center Copenhagen | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06803888 Comparator | Jan 2025 → Jul 2027 expected | obesity disorder | Ali Aminian | Active not recruiting | No outcome recorded |
| Phase 4 | NCT07325435 Comparator | Dec 2024 → Dec 2027 expected | type 2 diabetes mellitus | MaryAnn Banerji | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06613854 Comparator | Oct 2024 → Sep 2027 expected | type 2 diabetes mellitus | University Medical Centre Ljubljana | Recruiting | No outcome recorded |
| Phase 4 | NCT05702931 Comparator | Sep 2024 → Dec 2027 expected | diabetes mellitus, hyperglycemia | Rigshospitalet, Denmark | Recruiting | No outcome recorded |
| Phase 4 | NCT06449235 Comparator | Sep 2024 → Apr 2025 overdue | type 2 diabetes mellitus | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06533527 Comparator | Jul 2024 → May 2025 | gastroparesis, obesity disorder, type 2 diabetes mellitus | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 4 | NCT06184633 Comparator | Jul 2024 → May 2026 overdue | atrial fibrillation, obesity disorder | Rijnstate Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06374875 Comparator | Jul 2024 → May 2029 expected | NAFLD1, fibrotic liver disease, metabolic dysfunction-associated steatohepatitis, obesity disorder | Ali Aminian | Recruiting | No outcome recorded |
| Phase 4 | NCT06986993 Comparator | Jul 2024 → May 2028 expected | nicotine dependence | University of Oklahoma | Recruiting | No outcome recorded |
| Phase 4 | NCT06287307 Comparator | May 2024 → Feb 2026 overdue | morbid obesity | Zuyderland Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06410352 Comparator | Mar 2024 → Sep 2025 overdue | metabolic syndrome X | University Medical Center, Kazakhstan | Recruiting | No outcome recorded |
| Phase 4 | NCT06132477 Comparator | Feb 2024 → Jul 2028 expected | abdominal obesity-metabolic syndrome, diabetes mellitus, hypertensive disorder, morbid obesity +1 | University of Missouri-Columbia | Recruiting | No outcome recorded |
| Phase 4 | NCT05780905 Comparator | Jan 2024 → Mar 2026 overdue | stroke disorder, type 2 diabetes mellitus | University of Washington | Recruiting | No outcome recorded |
| Phase 4 | NCT05812183 Background | Jul 2023 → Feb 2025 | — | University of California, Los Angeles | Withdrawn | No outcome recorded |
| Phase 4 | NCT05441267 Comparator | Mar 2023 → Aug 2028 expected | type 2 diabetes mellitus | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05813249 Comparator | Feb 2023 → Feb 2024 | NAFLD1 | Zagazig University | Completed | No outcome recorded |
| Phase 4 | NCT05616052 Comparator | Dec 2022 → Dec 2023 | — | Huashan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05390892 Comparator | Sep 2022 → Mar 2029 expected | atherosclerotic cardiovascular disease, type 2 diabetes mellitus | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05371496 Comparator | Sep 2022 → Aug 2026 overdue | cardiomyopathy, diastolic heart failure, obesity disorder | Mayo Clinic | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05548647 Comparator | Jul 2022 → May 2025 | obesity disorder | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT05574439 Comparator | May 2022 → Apr 2026 | — | Signe Torekov | Completed | No outcome recorded |
| Phase 4 | NCT05303857 Comparator | Mar 2022 → Dec 2023 | type 2 diabetes mellitus | University of Erlangen-Nürnberg Medical School | Completed | No outcome recorded |
| Phase 4 | NCT04938388 Comparator | Jan 2022 → Feb 2023 | type 2 diabetes mellitus | Sansum Diabetes Research Institute | Terminated | No outcome recorded |
| Phase 4 | NCT05857085 Comparator | Dec 2021 → Mar 2022 | type 1 diabetes mellitus | General and Teaching Hospital Celje | Completed | No outcome recorded |
| Phase 4 | NCT04892199 Comparator | Sep 2021 → Mar 2026 overdue | schizophrenia, type 2 diabetes mellitus | Anders Fink-Jensen, MD, DMSci | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04624672 Comparator | Aug 2021 → Jul 2022 | type 2 diabetes mellitus | Geisinger Clinic | Terminated | No outcome recorded |
| Phase 4 | NCT04865744 Comparator | May → Sep 2021 | — | University of Tartu | Completed | No outcome recorded |
| Phase 4 | NCT04061200 Comparator | Nov 2019 → Jul 2021 | diabetic kidney disease | Steno Diabetes Center Copenhagen | Unknown | No outcome recorded |
| Phase 4 | NCT04126603 Comparator | Aug 2019 → Oct 2023 | type 2 diabetes mellitus | Sabyasachi Sen | Completed | No outcome recorded |
| Phase 4 | NCT03985384 Comparator | Apr 2019 → Dec 2022 | coronary atherosclerosis, type 2 diabetes mellitus | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT06863363 Comparator | — | obesity disorder | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase not applicable13 trials | ||||||
| — | NCT07713992 Comparator | Sep 2026 → Dec 2027 expected | NAFLD1, type 2 diabetes mellitus | Tianjin Medical University | Not yet recruiting | No outcome recorded |
| — | NCT07570810 Comparator | Jun → Nov 2026 expected | NAFLD1, obesity disorder, type 2 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| — | NCT07589322 Comparator | Mar 2026 → Sep 2028 expected | abdominal obesity-metabolic syndrome | Tri-Service General Hospital (TSGH) | Recruiting | No outcome recorded |
| — | NCT07317115 Comparator | Mar 2026 → Jun 2027 expected | obesity disorder, type 2 diabetes mellitus | GT Metabolic Solutions, Inc. | Recruiting | No outcome recorded |
| — | NCT07361874 Comparator | Mar 2026 → May 2030 expected | ACTH-independent Cushing syndrome | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| — | NCT06836284 Background | Feb 2026 → Apr 2027 expected | — | Karolinska Institutet | Recruiting | No outcome recorded |
| — | NCT07065383 Comparator | Aug 2025 → Jul 2028 expected | type 2 diabetes mellitus | University of Aberdeen | Recruiting | No outcome recorded |
| — | NCT06989177 Comparator | Jun 2025 → Dec 2026 expected | obesity disorder | Chinese Academy of Sciences | Recruiting | No outcome recorded |
| — | NCT06825793 Comparator | Feb 2025 → Dec 2026 expected | obesity disorder | Beijing Chao Yang Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06764056 Comparator | Jan 2025 → May 2026 overdue | metabolic dysfunction-associated steatohepatitis, obesity disorder | Institut universitaire de cardiologie et de pneumologie de Québec, University Laval | Not yet recruiting | No outcome recorded |
| — | NCT05984238 Comparator | Aug 2023 → Mar 2025 | type 2 diabetes mellitus | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| — | NCT05990374 Comparator | Aug 2023 → Jan 2024 | type 2 diabetes mellitus | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
| — | NCT05147896 Comparator | May 2022 → May 2023 | atherosclerosis, type 2 diabetes mellitus | University Medical Centre Ljubljana | Unknown | No outcome recorded |
Press releases naming this drug 85 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-05 | Novo Nordisk A/S | Novo Nordisk wins Dutch court injunction protecting patients from unapproved, unlawful compounded semaglutide nasal spray novonordisk.com ↗ |
| 2026-06-07 | Novo Nordisk A/S | Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026 novonordisk.com ↗ |
| 2026-06-06 | Novo Nordisk A/S | Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association's 2026 Scientific Sessions novonordisk.com ↗ |
| 2026-06-06 | Novo Nordisk A/S | People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data novonordisk.com ↗ |
| 2026-05-22 | Novo Nordisk A/S | Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1) novonordisk.com ↗ |
| 2026-05-22 | Novo Nordisk A/S | Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class novonordisk.com ↗ |
| 2026-04-02 | Novo Nordisk A/S | Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026 novonordisk.com ↗ |
| 2026-03-19 | Novo Nordisk A/S | Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss novonordisk.com ↗ |
| 2026-03-09 | Novo Nordisk A/S | Novo Nordisk expands US patient access to FDA-approved semaglutide medicines through Hims & Hers in response to a shift in their US GLP-1 business model novonordisk.com ↗ |
| 2026-02-24 | Novo Nordisk A/S | Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access novonordisk.com ↗ |
| 2026-02-09 | Novo Nordisk A/S | Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy® and Ozempic® novonordisk.com ↗ |
| 2026-01-05 | Novo Nordisk A/S | Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America novonordisk.com ↗ |
| 2025-12-22 | Novo Nordisk A/S | Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management novonordisk.com ↗ |
| 2025-11-26 | Novo Nordisk A/S | Novo Nordisk files for FDA approval of a higher dose of Wegovy® injection 7.2 mg novonordisk.com ↗ |
| 2025-11-10 | Novo Nordisk A/S | Novo Nordisk’s Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis novonordisk.com ↗ |
| 2025-11-05 | Novo Nordisk A/S | Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors novonordisk.com ↗ |
| 2025-10-28 | Novo Nordisk A/S | Novo Nordisk to present new Wegovy® (semaglutide 2.4 mg) data at the 2025 American Association for the Study of Liver Diseases annual meeting novonordisk.com ↗ |
| 2025-10-20 | Novo Nordisk A/S | Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025 novonordisk.com ↗ |
| 2025-08-15 | Novo Nordisk A/S | Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH novonordisk.com ↗ |
| 2025-06-02 | Regeneron Pharmaceuticals | Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass regeneron.com ↗ |
| 2025-01-17 | Novo Nordisk A/S | Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence novonordisk.com ↗ |
| 2024-12-12 | Novo Nordisk A/S | Novo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kidney disease-related events novonordisk.com ↗ |
| 2024-11-01 | Novo Nordisk A/S | Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial novonordisk.com ↗ |
| 2024-10-21 | Novo Nordisk A/S | Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial novonordisk.com ↗ |
| 2024-07-25 | Novo Nordisk A/S | European regulatory authority adopts a positive opinion for an update of the Wegovy® label to reflect risk reduction of major adverse cardiovascular events novonordisk.com ↗ |
| 2024-03-08 | Novo Nordisk A/S | Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease novonordisk.com ↗ |
| 2024-03-05 | Novo Nordisk A/S | Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial novonordisk.com ↗ |
| 2023-10-10 | Novo Nordisk A/S | Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis novonordisk.com ↗ |
| 2023-08-08 | Novo Nordisk A/S | Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial novonordisk.com ↗ |
| 2023-05-22 | Novo Nordisk A/S | Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the OASIS 1 trial novonordisk.com ↗ |
| 2023-03-24 | Novo Nordisk A/S | Oral semaglutide 25 mg and 50 mg demonstrate superior reductions in HbA1c and body weight versus 14 mg in people with type 2 diabetes in the PIONEER PLUS phase 3 trial novonordisk.com ↗ |
| 2022-03-28 | Novo Nordisk A/S | Ozempic® 2.0 mg approved in the US for the treatment of type 2 diabetes novonordisk.com ↗ |
| 2021-12-17 | Novo Nordisk A/S | Novo Nordisk announces supply challenges for Wegovy® in the US novonordisk.com ↗ |
| 2021-11-12 | Novo Nordisk A/S | Ozempic® 2.0 mg recommended for approval for the treatment of type 2 diabetes by the European Medicines Agency novonordisk.com ↗ |
| 2021-11-11 | Novo Nordisk A/S | Wegovy™ recommended for approval for the treatment of obesity by the European regulatory authorities novonordisk.com ↗ |
| 2021-06-04 | Novo Nordisk A/S | Wegovy™ (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US novonordisk.com ↗ |
| 2021-05-28 | Novo Nordisk A/S | Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval novonordisk.com ↗ |
| 2021-04-21 | Novo Nordisk A/S | Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide novonordisk.com ↗ |
| 2021-03-22 | Novo Nordisk A/S | Novo Nordisk receives Refusal to File letter for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes novonordisk.com ↗ |
| 2021-01-20 | Novo Nordisk A/S | Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes novonordisk.com ↗ |
| 2020-12-29 | Novo Nordisk A/S | Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes novonordisk.com ↗ |
| 2020-12-18 | Novo Nordisk A/S | Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.4 mg for weight management novonordisk.com ↗ |
| 2020-12-16 | Novo Nordisk A/S | Novo Nordisk to enter phase 3 development in Alzheimer’s disease with oral semaglutide novonordisk.com ↗ |
| 2020-12-04 | Novo Nordisk A/S | Novo Nordisk files for US FDA regulatory approval of once-weekly semaglutide 2.4 mg for weight management novonordisk.com ↗ |
| 2020-11-17 | Novo Nordisk A/S | Once-weekly semaglutide 2.0 mg demonstrates superior reduction in HbA1c vs once-weekly semaglutide 1.0 mg in people with type 2 diabetes in the SUSTAIN FORTE trial novonordisk.com ↗ |
| 2020-06-29 | Novo Nordisk A/S | Rybelsus® approved in Japan for the treatment of type 2 diabetes novonordisk.com ↗ |
| 2020-06-18 | Novo Nordisk A/S | Novo Nordisk successfully completes AM833 phase 2 trial and phase 1 combination trial with AM833 and semaglutide in obesity novonordisk.com ↗ |
| 2020-06-12 | Novo Nordisk A/S | Semaglutide 2.4 mg shows superior weight loss versus placebo in the phase 3 trials STEP 2 and STEP 3, thereby successfully completing the programme novonordisk.com ↗ |
| 2020-05-13 | Novo Nordisk A/S | Semaglutide 2.4 mg demonstrates superior and sustained weight loss versus placebo and in addition a 17.4% weight loss after 68 weeks in STEP 4 trial novonordisk.com ↗ |
| 2020-04-04 | Novo Nordisk A/S | Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2 diabetes in the EU novonordisk.com ↗ |
| 2020-01-31 | Novo Nordisk A/S | Rybelsus® (oral semaglutide) recommended for approval for the treatment of adults with type 2 diabetes by the European regulatory authorities novonordisk.com ↗ |
| 2020-01-16 | Novo Nordisk A/S | Ozempic® approved in the US for CV risk reduction in people with type 2 diabetes and established CVD novonordisk.com ↗ |
| 2019-09-20 | Novo Nordisk A/S | Rybelsus® (semaglutide tablets), the first GLP-1 in a tablet approved in the US novonordisk.com ↗ |
| 2019-04-26 | Novo Nordisk A/S | Novo Nordisk files for EU regulatory approval of oral semaglutide for the treatment of type 2 diabetes novonordisk.com ↗ |
| 2019-03-20 | Novo Nordisk A/S | Novo Nordisk files oral semaglutide for US regulatory approval of glycaemic control, as well as for CV risk reduction for oral semaglutide and Ozempic® novonordisk.com ↗ |
| 2018-11-23 | Novo Nordisk A/S | Oral semaglutide demonstrates favourable cardiovascular safety profile and significant reduction in cardiovascular death and all-cause mortality in people with type 2 diabetes in the PIONEER 6 trial novonordisk.com ↗ |
| 2018-11-22 | Novo Nordisk A/S | Oral semaglutide demonstrates greater reductions in both HbA1c and body weight compared to Victoza® in Japanese people with type 2 diabetes novonordisk.com ↗ |
| 2018-10-26 | Novo Nordisk A/S | Oral semaglutide demonstrates statistically significant reductions in HbA1c and body weight in people with long duration of type 2 diabetes treated with insulin novonordisk.com ↗ |
| 2018-09-20 | Novo Nordisk A/S | Novo Nordisk - Oral semaglutide demonstrates greater reductions in HbA1c and body weight and comparable number of adverse events vs dulaglutide in Japanese people with type 2 diabetes novonordisk.com ↗ |
| 2018-06-28 | Novo Nordisk A/S | Oral semaglutide shows superior reductions in HbA1c and weight compared to sitagliptin in the long-term safety and efficacy trial, PIONEER 3 novonordisk.com ↗ |
| 2018-06-20 | Novo Nordisk A/S | Oral semaglutide shows statistically significantly greater reductions in HbA1c and weight compared to Victoza® and sitagliptin in the PIONEER 4 and 7 trials novonordisk.com ↗ |
| 2018-05-29 | Novo Nordisk A/S | Oral semaglutide shows superior improvement in HbA1c vs empagliflozin in the PIONEER 2 trial novonordisk.com ↗ |
| 2018-03-23 | Novo Nordisk A/S | Ozempic® godkendt i Japan til behandling af type 2-diabetes novonordisk.com ↗ |
| 2018-03-23 | Novo Nordisk A/S | Ozempic® approved in Japan for the treatment of type 2 diabetes novonordisk.com ↗ |
| 2018-02-22 | Novo Nordisk A/S | Novo Nordisk successfully completes the first phase 3a trial, PIONEER 1, with oral semaglutide novonordisk.com ↗ |
| 2018-02-09 | Novo Nordisk A/S | Novo Nordisk A/S: Ozempic® (semaglutid) godkendt i EU til behandling af type 2-diabetes novonordisk.com ↗ |
| 2018-02-09 | Novo Nordisk A/S | Novo Nordisk A/S: Ozempic® (semaglutide) approved in the EU for the treatment of type 2 diabetes novonordisk.com ↗ |
| 2017-12-15 | Novo Nordisk A/S | Ozempic® (semaglutid) får anbefaling om godkendelse fra de europæiske lægemiddelmyndigheder novonordisk.com ↗ |
| 2017-12-15 | Novo Nordisk A/S | Ozempic® (semaglutide) recommended for approval by the European regulatory authorities novonordisk.com ↗ |
| 2017-12-05 | Novo Nordisk A/S | Ozempic® (semaglutid) godkendt i USA novonordisk.com ↗ |
| 2017-12-05 | Novo Nordisk A/S | Ozempic® (semaglutide) approved in the US novonordisk.com ↗ |
| 2017-10-18 | Novo Nordisk A/S | Semaglutide receives positive 16-0 vote in favour of approval from FDA Advisory Committee novonordisk.com ↗ |
| 2017-10-16 | Novo Nordisk A/S | Novo Nordisk: FDA posts briefing materials prior to Advisory Committee meeting for semaglutide novonordisk.com ↗ |
| 2017-08-16 | Novo Nordisk A/S | Semaglutide superior to dulaglutide on glucose control and weight loss in people with type 2 diabetes in SUSTAIN 7 novonordisk.com ↗ |
| 2017-06-23 | Novo Nordisk A/S | Novo Nordisk reports up to 13.8% weight loss in people with obesity receiving semaglutide in phase 2 trial novonordisk.com ↗ |
| 2017-02-28 | Novo Nordisk A/S | Novo Nordisk files for regulatory approval of once-weekly semaglutide for the treatment of type 2 diabetes in Japan novonordisk.com ↗ |
| 2016-12-05 | Novo Nordisk A/S | Novo Nordisk files for regulatory approval of once-weekly semaglutide in the US and EU for the treatment of type 2 diabetes novonordisk.com ↗ |
| 2016-04-28 | Novo Nordisk A/S | Semaglutide significantly reduces the risk of major adverse cardiovascular events in the SUSTAIN 6 trial novonordisk.com ↗ |
| 2016-02-23 | Novo Nordisk A/S | Novo Nordisk successfully completes fifth phase 3a trial with semaglutide in people with type 2 diabetes novonordisk.com ↗ |
| 2015-12-17 | Novo Nordisk A/S | Novo Nordisk successfully completes fourth phase 3a trial with semaglutide in people with type 2 diabetes novonordisk.com ↗ |
| 2015-09-25 | Novo Nordisk A/S | Novo Nordisk successfully completes second phase 3a trial with semaglutide in people with type 2 diabetes novonordisk.com ↗ |
| 2015-08-26 | Novo Nordisk A/S | Novo Nordisk to initiate phase 3a development of oral semaglutide, a once-daily oral GLP-1 analogue novonordisk.com ↗ |
| 2015-07-10 | Novo Nordisk A/S | Novo Nordisk successfully completes first phase 3a trial with semaglutide in people with type 2 diabetes novonordisk.com ↗ |
| 2015-02-20 | Novo Nordisk A/S | Novo Nordisk announces positive results for phase 2 trial with oral semaglutide in people with type 2 diabetes novonordisk.com ↗ |
| 2012-06-21 | Novo Nordisk A/S | Novo Nordisk to initiate phase 3 development of semaglutide, a once-weekly GLP-1 analogue novonordisk.com ↗ |
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 538 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | semaglutide | “Subjects will receive a glucagon-like peptide 1 receptor agonist (either semaglutide, tirzepatide or liraglutide) by self-injection or orally (semaglutide or orforglipron) for...” NCT07107334 ↗523“Weekly subcutaneous semaglutide/GLP-1 receptor agonist therapy administered according to approved labeling, clinical indication, patient tolerance, and endocrinology...” NCT07462663 ↗ “Receive 6 months of GLP-1RA (Semaglutide) treatment starting at 0.25mg once weekly and then the dose will be up titrated as tolerated every four weeks to once-weekly doses of...” NCT07178145 ↗ “BACKGROUND: Oral semaglutide is a novel tablet containing the human glucagon-like peptide-1 (GLP‑1) analogue semaglutide, co-formulated with the absorption enhancer sodium...” PMID 30565096 ↗ Jun 2019 “Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is an approved and well-established therapy for type 2 diabetes mellitus (T2DM), providing both robust glycemic...” NCT07563699 ↗ “Three incretin-based medications that have been approved for treatment of obesity including liraglutide, semaglutide, or tirzepatide will be used in the nonsurgical group.” NCT06374875 ↗ “Key question: Is the use of GLP-1 weight loss medicines - semaglutide and tirzepatide - associated with improvements in mental health and health-related quality of life?” NCT07368855 ↗ “IcoSema is a once-weekly combination therapy of basal insulin icodec (icodec) and semaglutide (a GLP-1 analogue) developed for the treatment of type 2 diabetes.” PMID 40482670 ↗ Jun 2025 “Wegovy®: Semaglutide injected once weekly, starting dose 0.25mg, with dose increments every four weeks reaching the maintenance dose of 1mg after eight weeks” NCT06715514 ↗ “The glucagon-like peptide-1 receptor agonist semaglutide is approved for the treatment of type 2 diabetes and obesity and has an established safety profile.” PMID 39780249 ↗ Jan 2025 “Chemical Name: GLP-1 Receptor Agonists (GLP1RA) (e.g., Exenatide, Liraglutide, Dulaglutide, Semaglutide) Class: Glucagon-Like Peptide-1 Receptor Agonists” NCT06449235 ↗ “In this study, patients received standard clinical doses (e.g., liraglutide 1.2-1.8 mg once daily or semaglutide 0.5-1.0 mg once weekly) for 6 months.” NCT07539584 ↗ “Agents may include incretin-based therapies (e.g., Semaglutide, Tirzepatide) or other FDA-approved AOMs such as Topiramate or Phentermine.” NCT07058155 ↗ “Two specific GLP-1RAs are used in this study: semaglutide at 0.5 mg once weekly, or polyethylene glycol loxenatide at 0.2 mg once weekly.” NCT07558863 ↗ “The choice of AOMs considered may include metformin, topiramate, liraglutide, dulaglutide, semaglutide, tirzepatide, and empagliflozin.” NCT07027969 ↗ “GLP-1 receptor agonists (GLP-1 RAs), such as semaglutide, have demonstrated strong effects on weight loss in individuals with obesity.” NCT07314528 ↗ “0.25mg once weekly for 4 weeks followed by 0.5mg once weekly for 74 weeks via subcutaneous injection for Ozempic (semaglutide)” NCT05356104 ↗ “Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist used for management of type 2 diabetes and/or obesity.” PMID 36870274 ↗ Mar 2023 “Semaglutide 0.25 mg once weekly (qw) + Empagliflozin 10 mg once daily (qd) + Pioglitazone 15 mg once daily (qd)” NCT06946628 ↗ “Semaglutide 2.4 mg subcutaneous once-weekly starting 3 months prior TAVR and continued 24 months post-TAVR.” NCT07090343 ↗ “Preliminary Safety and Efficacy of Semaglutide and Naltrexone Combination Therapy for Alcohol Use Disorder” NCT07249554 ↗ “Cagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously using device 1 or device 2.” NCT07357766 ↗ “The secondary aims are to assess the effect of semaglutide for perioperative optimization in TKR” NCT06807970 ↗ “Cagrilintide and Semaglutide will be administered subcutaneously using device 1 or device 2.” NCT07357740 ↗ “Initiation/intensification of weight loss medications, such as semaglutide or tirzepatide” NCT07223242 ↗ “Liraglutide: 6 mg/ml Semaglutide: 1.34 mg/ml Dulaglutide: de 0.75 mg ou 1.5 mg” NCT03498001 ↗ “Semaglutide 1mg/1ml administered in PCCA sub-magna compounding base only.” NCT07092605 ↗ “Patients self-inject Semaglutide once a week or use other GLP-1RAs” NCT06924697 ↗ “Semaglutide, administered once weekly as a subcutaneous injection.” NCT07392151 ↗ “Semaglutide is a Glucagon-Like Peptide 1 Receptor Agonist.” NCT05205928 ↗ “This includes semaglutide, tirzepitide, among others.” NCT06132477 ↗ “the GLP-1RA semaglutide on the bone formation marker” PMID 38737002 ↗ May 2024 “Microneedle patch containing Semaglutide” NCT07539415 ↗ “Dulaglutide, liraglutide, semaglutide” NCT05390892 ↗ “Names for drugs: Semaglutide.” NCT07336862 ↗ “semaglutide (Ozempic)” NCT07325435 ↗ “Semaglutide (Wegovy)” NCT05812183 ↗ “Oral Semaglutide” NCT05813249 ↗ “semaglutide” NCT04019197 ↗ |
| Known as | Fitaro | “In Bangladesh, semaglutide (Fitaro) is available for weight management at various doses (0.25 mg to 2.4 mg)” NCT06616961 ↗ |
| Known as | NN-9535 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108724 ↗ |
| Known as | NNC0113-0217 | “Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide (NNC0113-0217)” NCT02016911 ↗1“oral semaglutide (NNC0113-0217)” NCT02070510 ↗ |
| Known as | NPM-139 | “Semaglutide Implant (NPM-139) is a drug/device combination product consisting of a subdermal titanium implant \~23 mm long and 2 mm in diameter, containing a sterile liquid...” NCT07430059 ↗ |
| Known as | Ozempic | “If possible, patients will be placed on high-dose tirzepatide (Mounjaro or Zepbound 15 mg once weekly injection) or high-dose semaglutide (Wegovy 2.4 mg once weekly injection...” NCT06374875 ↗26“Such an approach is now in particular of relevance, since the European Medicines Agency (EMA) has already approved semaglutide s.c. (Ozempic) and semaglutide in an oral formula...” NCT05303857 ↗ “Semaglutide is already approved in several formulations (examples: Ozempic® for type 2 diabetes and Wegovy® for weight management), but these require once-weekly injections.” NCT07563699 ↗ “GLP-1 medications such as semaglutide (e.g. Ozempic) are approved for diabetes and medication, and may potentially affect craving for other substances apart from food.” NCT07509112 ↗ “Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) that is FDA-approved for the treatment of obesity (as Wegovy) or T2DM (as Ozempic).” NCT06005012 ↗ “New medicines called GLP-1 receptor agonists, like semaglutide (Ozempic) and tirzepatide (Mounjaro), help people lose weight and improve health.” NCT07179120 ↗ “Upon introduction of semaglutide (ozempic) treatment, insulin doses will be reduced by 10% (basal insulin, basal rate and bolus)” NCT05305794 ↗ “combined with a GLP-1 receptor agonist (Semaglutide, Ozempic) in subjects with insulin-dependent type 2 diabetes mellitus.” NCT05984238 ↗ “The Effect of Semaglutide (Ozempic) on Bone Turnover in Patients With Increased Fracture Risk” NCT04702516 ↗ “Semaglutide, Ozempic® (at maximum tolerated dose) + Automated Insulin Delivery system” NCT06894784 ↗ “Weekly semaglutide (Ozempic®) injections on regular closed-loop insulin pump therapy” NCT06387199 ↗ “Semaglutide, Ozempic® (at maximum tolerated dose) + closed-loop insulin system” NCT05205928 ↗ “Up to 1.0 mg semaglutide (Ozempic®) Metformin ≥ 1500 mg/day” NCT06161844 ↗ “Group 1: semaglutide (Ozempic®) (by injection into skin)” NCT03596450 ↗ “Semaglutide Injectable Product (Wegovy and/or Ozempic)” NCT05819853 ↗ “Semaglutide Injection （Ozempic®）1.0 mg” NCT07163624 ↗ “Semaglutide 1MG Injection [Ozempic]” NCT03292315 ↗ “Semaglutide Pen Injector [Ozempic]” NCT06449625 ↗ “Semaglutide Pen Injector [Ozempic]” NCT05606471 ↗ “Semaglutide Pen Injector [Ozempic]” NCT05950516 ↗ “Semaglutide Pen Injector [Ozempic]” NCT05857085 ↗ “Semaglutide 1.34 MG/ML [Ozempic]” NCT05078255 ↗ “Semaglutide (Ozempic®)” NCT07614412 ↗ |
| Known as | Ozempyc | “Subcutaneous semaglutide (Ozempyc, Novo Nordisk A/S Bagsvaerd, Denmark)” NCT06541509 ↗ |
| Known as | Rybelsus | “Such an approach is now in particular of relevance, since the European Medicines Agency (EMA) has already approved semaglutide s.c. (Ozempic) and semaglutide in an oral formula...” NCT05303857 ↗24“Once daily semaglutide tablets (3 mg, 7 mg and 14 mg) are approved for the treatment of type 2 diabetes in the US, in the EU and in some other countries, under the brand name Rybelsus®.” NCT04707469 ↗ “Other acceptable, less preferrable, options: liraglutide (Saxenda or Victoza), semaglutide tablet (Rybelsus), or lower dose of tirzepatide and semaglutide injections.” NCT06374875 ↗ “Oral semaglutide (Rybelsus®) was purchased and then repackaged into capsules looking identical to DGE, CQE and placebo capsules.” NCT06827002 ↗ “Currently, doses of 3 milligram (mg), 7 mg and 14 mg semaglutide tablets (Rybelsus) can be prescribed in some countries.” NCT06083675 ↗ “Semaglutide tablets, under the brand name Rybelsus, are approved in the EU and USA for the treatment of type 2 diabetes.” NCT05996874 ↗ “semaglutide (Rybelsus®) 3 mg daily for 4 weeks followed by 7 mg daily for 4 weeks, hereafter 14 mg daily” NCT07135245 ↗ “Participants receive 7mg of semaglutide (Rybelsus®) orally once before one of the post-TZIELD® MMTTs.” NCT06338553 ↗ “semaglutide/Rybelsus will be administered as a single oral dose” NCT06608433 ↗ “Arm 4 - Rybelsus medication (semaglutide) alone” NCT06648031 ↗ “Semaglutide 3mg and 7mg [Rybelsus]” NCT03919929 ↗ “called oral semaglutide (Rybelsus)” NCT06003153 ↗ “Semaglutide 14 MG [Rybelsus]” NCT07254572 ↗ “Semaglutide 14 MG [Rybelsus]” NCT06913023 ↗ “oral Semaglutide/Rybelsus” NCT06050577 ↗ “Semaglutide (Rybelsus®)” NCT07200622 ↗ “Semaglutide (Rybelsus®)” NCT07179120 ↗ “Semaglutide (Rybelsus®)” NCT07221214 ↗ “Semaglutide (Rybelsus®)” NCT07295223 ↗ “Semaglutide (Rybelsus®)” NCT07297589 ↗ “Semaglutide (Rybelsus®)” NCT07401992 ↗ “Semaglutide (Rybelsus®)” NCT07642635 ↗ |
| Known as | SEMA | “randomised to semaglutide (SEMA) 1 mg/week or intramuscular testosterone undecanoate (TRT) 1000 mg/10-12 weeks for 24 weeks” PMID 39511836 ↗ Nov 20243“Drug: Semaglutide (SEMA)” NCT07586150 ↗ “Semaglutide (SEMA)” NCT04971785 ↗ “Semaglutide (SEMA)” NCT07389941 ↗ |
| Known as | Semagluide | “Semagluide” NCT07539415 ↗ |
| Known as | Semaglutida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108724 ↗ |
| Known as | semaglutide (Ozempic) | “semaglutide (Ozempic)” NCT07325435 ↗ |
| Known as | Semaglutide component of cagrisema | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108724 ↗ |
| Known as | Semaglutide component of nn1535 icosema | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108724 ↗ |
| Known as | Semaglutide component of nn1535 laisema | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108724 ↗ |
| Known as | semaglutide I | “Participants will receive a single subcutaneous (s.c.) dose of CagriSema (cagrilintide B and semaglutide I) in DV3384 pen-injector in period 1 followed by a single s.c. dose of...” NCT06716307 ↗ |
| Known as | Semaglutide Injection | “Semaglutide Injection, 0.68 mg/mL，1.5 mL；1.34 mg/mL，1.5 mL；1.34 mg/mL，3 mL；2.27 mg/mL，3 mL；3.2 mg/mL，3 mL; Subcutaneous injection once weekly using pre-filled pen including...” NCT06863363 ↗ |
| Known as | Semaglutide Pen | “Drug: Semaglutide Pen” NCT06616961 ↗ |
| Known as | TQF3510 | “This is a multicenter, randomized, open, parallel, positive-controlled clinical study to evaluate the efficacy and safety of Semaglutide injection (TQF3510) developed by Chia...” NCT06738979 ↗ |
| Known as | Wegovy | “The intervention consists of once-weekly subcutaneous semaglutide (Wegovy®), initiated at 0.25 mg and uptitrated to a target dose of 2.4 mg as tolerated, administered for at...” NCT07275697 ↗21“The GLP-1 agonist class of drugs, including semaglutide (Wegovy®), have been approved for the treatment of patients as an adjunct to diet and exercise and for weight loss in...” NCT06754163 ↗ “If possible, patients will be placed on high-dose tirzepatide (Mounjaro or Zepbound 15 mg once weekly injection) or high-dose semaglutide (Wegovy 2.4 mg once weekly injection...” NCT06374875 ↗ “Semaglutide is already approved in several formulations (examples: Ozempic® for type 2 diabetes and Wegovy® for weight management), but these require once-weekly injections.” NCT07563699 ↗ “Wegovy®: Semaglutide injected once weekly, starting dose 0.25mg, with dose increments every four weeks reaching the maintenance dose of 1mg after eight weeks” NCT06715514 ↗ “Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) that is FDA-approved for the treatment of obesity (as Wegovy) or T2DM (as Ozempic).” NCT06005012 ↗ “Semaglutide (Wegovy) is a clear, colorless solution provided as Wegovy FlexTouch four-dose pens: 0.25 mg/0.5 mL.” NCT07430059 ↗ “semaglutide (Wegovy) once-weekly by subcutaneous injection, titrated to a maximum dose of 2.4 mg.” NCT07523633 ↗ “semaglutide injection or WEGOVY® injection will be given once weekly” NCT07036172 ↗ “All participants in the study will receive semaglutide (Wegovy).” NCT07282769 ↗ “commercially available semaglutide injection (Wegovy®)” NCT06577090 ↗ “Semaglutide Injectable Product (Wegovy and/or Ozempic)” NCT05819853 ↗ “Semaglutide (Wegovy) once-weekly injection s.c” NCT07136714 ↗ “Semaglutide (Wegovy) weekly injection” NCT07446998 ↗ “Semaglutide(Wegovy® )” NCT07150975 ↗ “Semaglutide (Wegovy®)” NCT07621640 ↗ “Semaglutide (Wegovy)” NCT05812183 ↗ “Semaglutide (Wegovy)” NCT07204249 ↗ “Other Name: Wegovy” NCT05746039 ↗ |
| Action | Activate | “GLP-1 receptor agonist drug class” PMID 30565096 ↗ Jun 2019 |
| Modality | Peptide | “Semaglutide, a Human Glucagon-Like Peptide-1 Analog” PMID 28349386 ↗ Nov 2017 |
| Route | Subcutaneous | “subcutaneous injection of semaglutide once weekly” PMID 26358288 ↗ Sep 2015 |
| Target | GLP1R | “a glucagon-like peptide-1 (GLP-1) receptor agonist” PMID 31189520 ↗ Jun 2019 |